Daiichi Sankyo Company Limited and Ranbaxy Laboratories Limited, today announced that Ranbaxy would launch Olmesartan Medoxomil, an anti-hypertensive drug originally synthesised by Daiichi Sankyo, in six African countries.
The six countries are, Kenya, Mozambique, Nigeria, Tanzania, Uganda, and Zambia. The companies made a statement to that effect on Monday.
The product to be marketed under the brand name Olvance would be launched immediately on completion of the required formalities in each country.
Takashi Shoda, president and CEO of Daiichi Sankyo said that he was delighted to announce the introduction of Olvance in Africa through Ranbaxy's network.
He added that it was the first time in Africa that the two companies were leveraging mutual synergies generated through the Hybrid Business Model and that they would continue to explore other collaborations with Ranbaxy that will help deliver their innovative products to patients throughout the globe.
Atul Sobti, CEO and managing director of Ranbaxy, said, Ranbaxy had a significant presence in the African continent. The company would utilise its strong business network to bring the innovative medicines of Daiichi Sankyo to the African people.